Vaxcyte, Inc.
PCVX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001649094
In the last 90 days, Vaxcyte, Inc. insiders filed 0 open-market purchases and 8 sales; 331 institutions reported holding it in 13F filings for Q2 2026, worth $9.71B in total; Maverick Capital is the only superinvestor holding it.
Q3 2022 vs. Q2 2022
How the institutions holding Vaxcyte, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 106 | 126 | +20 |
| Shares | 51.4M | 56.5M | +5.05M (+9.8%) |
| Value | $1.12B | $1.36B | +$237.0M (+21.2%) |
New holders (26)
Institutions that held Vaxcyte, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (6)
Institutions that held Vaxcyte, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Ikarian Capital, LLC | 225,991 | $4.92M |
| Gyon Technologies Capital Management, LP | 27,105 | $590.0K |
| Boothbay Fund Management, LLC | 22,733 | $495.0K |
| Trexquant Investment LP | 16,851 | $367.0K |
| Qube Research & Technologies Ltd | 13,820 | $301.0K |
| Voloridge Investment Management, LLC | 12,475 | $271.0K |